It looks like you're using an Ad Blocker.
Please white-list or disable AboveTopSecret.com in your ad-blocking tool.
Some features of ATS will be disabled while you continue to use an ad-blocker.
(visit the link for the full news article)
Today, the Association for Molecular Pathology (AMP) asked the U.S. Patent and Trademark Office (USPTO) to place a moratorium on the issuing of patents on human genes during testimony presented at an Agency hearing on genetic diagnostic testing. AMP is the lead plaintiff of 20 plaintiffs in an American Civil Liberties Union (ACLU) sponsored lawsuit challenging the validity of patents on two hereditary breast and ovarian cancer genes, BRCA1 and BRCA2. AMP joined the litigation .....
"Patients are increasingly being harmed by patents that claim ownership over the biological relationships between genetic variants and clinical disease," stated Roger D. Klein, MD JD, Chair of AMP's Professional Relations Committee. For example, a method patent relating to a variation in a gene known as FLT3 that is used to qualify some leukemia patients for bone marrow transplant is forcing physicians and laboratories to split and geographically distribute irreplaceable bone marrow specimens. "Splitting samples not only creates an additional risk of specimen loss and delays the receipt of patient results," stated Dr. Klein, "it interferes with the ability of pathologists to provide synoptic interpretations involving multiple tests and prevents them from implementing cost saving algorithms that restrict testing to those tests that are truly necessary."
Originally posted by Kali74
I had no idea this was even going on...pure insanity and terrifying.
Genetic Research and Legislative Needs
While writing Next, Crichton concluded that laws covering genetic research desperately needed to be revised, and spoke to Congressional staff members about problems ahead. A Talk to Legislative Staffers Washington, D.C. September 14, 2006
Next is a 2006 techno-thriller novel by Michael Crichton, the last to be published during his lifetime. Next takes place in the present world, where both the government and private investors spend billions of dollars every year on genetic research. The novel follows many characters, including transgenic animals, in the quest to survive in a world dominated by genetic research, corporate greed, and legal interventions.
In an appendix the author argues against patents on naturally-occurring genes, against corporate ownership of individuals' cell lines, and in favor of legislation to abolish these.